• Jacob R Miller, Deirdre J Epstein, Matthew C Henn, Tracey Guthrie, Richard B Schuessler, Kathleen E Simpson, Charles E Canter, Pirooz Eghtesady, and Umar S Boston.
• From the *Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, Missouri; †Section of Pediatric Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, Missouri; and ‡Section of Pediatric Cardiology, Washington University School of Medicine, St. Louis, Missouri.
• ASAIO J. 2015 Nov 1; 61 (6): 688-94.

AbstractBiventricular assist device (BiVAD) support is considered a risk factor for worse outcomes compared with left ventricular assist device (LVAD) alone for children with end-stage heart failure. It remains unclear whether this is because of the morbidity associated with a second device or the underlying disease severity. We aimed to show that early BiVAD support can result in good survival by analyzing our prospectively collected database for all pediatric patients who underwent BiVAD implantation. From 2005 to 2009, BiVADs were used exclusively. From 2010 to 2014, LVAD alone was considered, maintaining a low threshold for BiVAD support. All BiVADs were pulsatile devices. Thirty-one patients with median age of 3.5 years received BiVAD support. Diagnoses included dilated cardiomyopathy in 17 (55%), myocarditis in 6 (19%), and congenital heart disease in 3 (10%). Survival to transplant was achieved in 27 (87%) with a median duration of 41 days (interquartile range, 15-69). Adverse event rates (per 100 days of support) were bleeding at 0.52, infection at 1.17, and central nervous system dysfunction at 0.78. Of those who survived to transplant, 26 (96%) remain alive with a median follow-up of 55 months. These results show that BiVAD support can bridge patients to transplant with excellent long-term survival.

13 keywords...

hide…